Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is segmented by Type of Cancer (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), by Product, and Geography.

Market Snapshot

Market Snapshot1
Study Period: 2018 - 2026
Base Year: 2019
CAGR: 2.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 2.5% during the forecast period. The major factors driving the growth of the market in the Asia region is due to growing awareness about Uterine diseases and their available therapies, increasing health care expenditure and innovation in drug development, and subsequent technological advancements.

According to Cancer Australia, estimated that in 2016, there were about 527 deaths from uterine cancer in Australia. In 2019, it was estimated at around 562 deaths. In addition, it also stated that the risk of a female dying from uterine cancer will be 1 in 205.

Furthermore, governments are provoking awareness programs in certain Asia-Pacific regions. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly over the forecast period.

Scope of the report

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is segmented by type of cancer, product, and geography.

By Cancer Type
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
By Product
Radiation Therapy
Other Therapeutics
Pelvic Ultrasound
Dilation and Curettage
CT Scan
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

Key Market Trends

Endometrial Adenocarcinoma is Expected to Witness Highest Growth Over the Forecast Period in the Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market

The major factors driving the growth of the segment is due to the growing burden of endometrial adenocarcinoma. For instance, as per Cancer Australia, in 2019, it is estimated that the age-standardized incidence rate of uterine cancer was about 20 cases per 100,000 females in Australia. The incidence rate for uterine cancer was expected to increase with age, peaking at age group 65–69.

Furthermore, as per the Journal of Gynecological Oncology 2020, endometrial cancer is a major gynecologic malignancy with the highest rate among patients with gynecologic malignant tumors in Japan. In Japan, the age-adjusted mortality rate of endometrial cancer was 2.0 in 2017. In addition, in Australia, there were about 3,115 (4.7%) new cases of uterine cancer diagnosed in 2019 as per Cancer Australia. Thus, owing to the above factors the segment is expected to show growth in the coming years.

APAC uterine key trend 1.png

Competitive Landscape

The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is consolidated competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share. Some of the companies involved in the market are Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, GlaxoSmithKline Plc and Novartis AG.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure

      3. 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs

      2. 4.3.2 High Cost Associated With the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Adenocarcinoma

      2. 5.1.2 Adenosquamous Carcinoma

      3. 5.1.3 Papillary Serous Carcinoma

      4. 5.1.4 Uterine Sarcoma

    2. 5.2 By Product

      1. 5.2.1 Therapeutics

        1. Surgery

        2. Immunotherapy

        3. Radiation Therapy

        4. Chemotherapy

        5. Other Therapeutics

      2. 5.2.2 Diagnostics

        1. Biopsy

        2. Pelvic Ultrasound

        3. Hysteroscopy

        4. Dilation and Curettage

        5. CT Scan

    3. 5.3 Geography

      1. 5.3.1 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific


    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co., Inc

      2. 6.1.2 Eisai.Co.Ltd

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Takeda Pharmaceutical Company Limited

      6. 6.1.6 Siemens Healthcare Inc

      7. 6.1.7 GlaxoSmithKline Plc

      8. 6.1.8 Novartis AG

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The APAC Uterine Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The APAC Uterine Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 2.5% over the next 5 years.

Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited are the major companies operating in APAC Uterine Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!